Previous 10 | Next 10 |
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quar...
2024-04-17 17:01:03 ET Gainers: Vanda Pharmaceuticals ( VNDA ) +7% . Sutro Biopharma ( STRO ) +5% . CureVac ( CVAC ) +5% . CorMedix ( CRMD ) +4% . Bank OZK ( OZK ) +4% . Losers: Omega Therapeutics ( OM...
2024-03-22 03:31:05 ET More on Eton Pharmaceuticals, Relief Therapeutics Holding SA, etc. Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Eton Pharmaceuticals Historical earnings data for Eton Pharmaceuticals ...
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point Transaction is expected to be accretive to 2024 earnings Estimated peak sales of more than $10 million annually U.S. phenylketonuria ("PKU"...
2024-03-15 10:00:13 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...
2024-03-14 21:38:06 ET Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Results Conference Call March 14, 2024 04:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer C...
2024-03-14 16:10:43 ET More on Eton Pharmaceuticals Seeking Alpha’s Quant Rating on Eton Pharmaceuticals Historical earnings data for Eton Pharmaceuticals Financial information for Eton Pharmaceuticals Read the full article on Seeking Alpha For...
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growth Full year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022 Announce...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quar...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
2024-05-06 09:00:05 ET Chase Knickerbocker from Craig-Hallum issued a price target of $8.00 for ETON on 2024-05-06 07:29:00. The adjusted price target was set to $8.00. At the time of the announcement, ETON was trading at $3.71. The overall price target consensus is at $...